Thursday, February 25, 2021

7:30 - 8:45am SS1. Industry Supported CME Satellite Symposium*
Rethinking Routines in Multiple Sclerosis Management: What the Future Holds for DMTs and Cognitive Assessment Strategies
This CME activity is provided by CME Outfitters, LLC. This independent Industry Supported Satellite Symposium is supported by an educational grant from Bristol-Myers Squibb Company.
8:45am - 9:00am BREAK
9:00 - 10:00am KJ1. Opening Address & Kenneth P. Johnson Memorial Lecture
Chairs: Jeffrey A. Cohen, Cleveland Clinic and Anne Cross, Washington University in St. Louis
Lecturer: Benjamin M. Segal, The Ohio State University
10:00 - 10:45am BA1. National Multiple Sclerosis Society (NMSS) Barancik Award Presentation and Talk
10:45 - 11:00am BREAK
11:00am - 12:30pm S1. Session 1 - Emerging Concepts in MS
Pavan Bhargava, Johns Hopkins University
Highlighting cutting-edge studies that inform our understanding of the pathogenic mechanisms in MS, introduce novel measures to capture disease activity, and advance treatment options for affected individuals. This session will be comprised of six platform presentations by Young Investigators selected from submitted abstracts.
  11:00-11:05am Introduction
  11:05-11:15am S1.1 Associations of Serum Neurofilament Light Chain with Clinical and Radiological Measures in a Large Real World MS Population
Elias Sotirchos, Johns Hopkins University
  11:15 - 11:25am S1.2 Role of MCAM+ Regulatory T Cells in Multiple Sclerosis
Jennifer Sebali, Centre de Recherche du Centre Hospitalier de l'Université de Montréal
  11:25 - 11:35am S1.3 Low Sun Exposure is a Risk Factor for Pediatric-Onset Multiple Sclerosis
Prince Sebastian, Australian National University
  11:35 - 11:45am S1.4 Adult-Onset Genetic Leukodystrophies Misdiagnosed as Multiple Sclerosis in Clinical Practice
Alise Carlson, Cleveland Clinic
  11:45 - 11:55am S1.5 Characteristics and Predictors of Disease Course in Children Initially Presenting with ADEM
Alice Rutatangwa, University of California, San Francisco
  11:55 - 12:05pm S1.6 Single Cell and Spatial RNA Sequencing Identify Candidates that Drive Aging-Exacerbated Neurodegeneration in the Spinal Cord
Yifei Dong, University of Calgary
  12:05 - 12:30pm Q&A Discussion
12:30 - 12:45pm BREAK
12:45 - 2:15pm S2. Session 2 - The Spectrum of MS Across the Lifespan
Chairs: Riley Bove, University of California, San Francisco
Rose-Marie Rébillard, Université de Montréal
Theme: This session examines the effects of extremes in age on MS, and the effects of aging on the CNS recovery capacity.
Learning Objectives: 1) To define the effects of MS on cognition in pediatric-age MS patients; 2)To examine how aging and menopause alter remyelination and recovery from MS disease activity
  12:45 - 12:50pm Introduction
  12:50 - 1:05pm S2.1 Pediatric Onset-Effects on Cognition and Long-Term Learning
Lauren Krupp, NYU Langone Health
  1:05 - 1:20pm S2.2 Aging and Rejuvenation of Oligodendrocytes
Tal Iram, Stanford University
  1:20 - 1:35pm S2.3 Effects of Aging on MS
Jennifer Graves, University of California, San Diego
  1:35 - 1:50pm S2.4 Menopause and Hormonal Effects
Rhonda Voskuhl, University of California, Los Angeles
  1:50 - 2:15pm Q&A Discussion
2:15 - 2:30pm BREAK

2:30 - 3:45pm

SS2. Industry Supported CME Satellite Symposium*
The Rise of B Cell Therapies in Relapsing MS: Examining the State of the Science, New Therapeutic Options, and Patient-Centered Clinical Decision-Making
This CME activity is jointly provided by PeerView Institute for Medical Education (PVI) and the Medical Learning Institute, Inc. This independent Industry Supported Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.
3:45 - 4:15pm Brain Exchange Group Discussions: Disparities in Care in MS and Long-Term Safety Data

Friday, February 26, 2021

8:00 - 9:15am SS3. Industry Supported CME Satellite Symposium*
Upgrading the Standard of Care for Neuromyelitis Optica Spectrum Disorder (NMOSD): Novel Therapies
This CME activity is provided by Med Learning Group. This independent Industry Supported Satellite Symposium is supported by an educational grant from Genentech, A Member of the Roche Group.
9:15 - 9:45am Brain Exchange Group Discussions: COVID-19 & MS and Recognizing & Managing Early Disease Progression in MS
9:45 - 10:00am BREAK
10:00 - 11:30am S3. Session 3 - LACTRIMS - The Spectrum of MS in the Hispanic and Latino Populations
Chairs: Daniel Ontaneda, Cleveland Clinic
Fernando Hamuy, Universidad Nacional de Asunción
Theme: This session will focus on the manner in which MS affects Hispanic and Latino populations in the Caribbean, Central and South America.
Learning Objectives: 1) To examine the demographic and clinical spectrum of MS in Hispanic and Latino populations; 2) To learn about the impact of obesity and the microbiome on MS in Hispanic/Latino population
  10:00 - 10:05am Introduction
  10:05 - 10:20am S3.1 The Reality of MS Epidemiology in LATAM
Victor Rivera, Baylor College of Medicine
  10:20 - 10:35pm S3.2 The Relationship Between Obesity and MS Metabolic-Immunological Interaction
Jorge Correale, Raúl Carrea Institute for Neurological Research (FLENI), Argentina
  10:35 - 10:50am S3.3 Spectrum of MS Demographics in LATAM Population
Fernando Gracia, ULACIT University, Panama
  10:50 - 11:05pm S3.4 MS and Intestinal Microbiota in LATAM Population
Viviana Orozco, University of Puerto Rico, Medical Sciences Campus
  11:05 - 11:30am Q&A Discussion
11:30 - 11:45am BREAK
11:45am - 1:30pm CE1. Cutting Edge Developments
Chairs: Scott Zamvil, University of California, San Francisco
Jo Anne Stratton, McGill University
Theme: This session will be comprised of two presentations from invited speakers followed by five groundbreaking platform presentations selected from submitted abstracts.
Learning Objectives: 1) To learn about effects of MS and DMTs on COVID-19 development and recovery; 2) To examine what is known regarding effects of DMTs on response to vaccinations; 3) To learn about new research developments in MS considered to be "groundbreaking".
  11:45 - 11:50am Introduction
  11:50am - 12:05pm CE1.1 COVID-19 and MS-Registry Information
Amber Salter, Washington University in St. Louis
  12:05 - 12:20pm CE1.2 Vaccination Responses in Setting of Different Types of MS DMTs
Amit Bar-Or, University of Pennsylvania
  12:20 - 12:30pm CE1.4 Patterns of Disease-Modifying Treatment Use and Sociodemographic Characteristics in Multiple Sclerosis by Race and Ethnicity
Carlos Pérez, The University of Texas Health Science Center at Houston
  12:30 - 12:40pm CE1.5 Human Oligodendrocyte Lineage and Functional States Revealed by Single-Cell RNA Sequencing Analysis
Julia Luo, McGill University
  12:40 - 12:50pm CE1.6 Adenosine 2A Receptor Expression in Progressive MS is Associated with Astroglial Pan-activation and High Oxidative Toxicity
Chih Lo, Yale University
  12:50 - 1:00pm CE1.7 Quantification of Meningeal Enhancing Volume Reveals Relationships with Clinical Outcomes and Cortical Thinning on 7T MRI in MS
Claire Allen, University of Maryland
  1:00 - 1:30pm Q&A Discussion
1:30 - 1:45pm BREAK
1:45 - 2:15pm Brain Exchange Group Discussions: Sequencing of Medication and NMOSD
2:15 - 2:45pm Poster Session 1 - Imaging
2:45 - 3:15pm Poster Session 2 - Biomarkers/Central Vein Sign
3:15 - 3:30pm BREAK
3:30 - 4:00pm Poster Session 3 - Basic Science
4:00 - 4:30pm Poster Session 4 - Clinical

Saturday, February 27, 2021

7:30 - 8:45am SS4. Industry Supported CME Satellite Symposium*
Addressing Healthcare Disparities and COVID-19 Concerns For All Patients with Multiple Sclerosis
This CME activity is provided by AcademicCME. This independent Industry Supported Satellite Symposium is supported by educational grants from Biogen, Bristol-Myers Squibb Company and Sanofi Genzyme.
8:45 - 9:00am BREAK
9:00 - 10:30am S4. Session 4 - The Spectrum of Inflammation and Environmental Impacts on Inflammation
Chairs: Ruth Ann Marrie, University of Manitoba
Lindsey Wooliscroft, Oregon Health Science University
Theme: This session will focus on the impact of different environmental factors on inflammation and pathophysiology in relation to MS.
Learning Objectives: 1) To learn about inflammasomes and pyroptosis in relation to MS; 2) To examine nutritional and metabolic factors that impact MS pathophysiology
  9:00 - 9:05am Introduction
  9:05 - 9:20am S4.1 Inflammasomes and Pyroptosis in MS
Chris Power, University of Alberta
  9:20 - 9:35am S4.2 Mechanisms of Inflammation – Vitamin D Effects on Myeloid Cells
Luke Healy, McGill University
  9:35 - 9:50am S4.3 Weight, Obesity and Adipokines
Laura Piccio, Washington University in St. Louis
  9:50 - 10:05am S4.4 Impact of Methionine Intake on Inflammation
Catherine Larochelle, Université de Montréal
  10:05 - 10:30am Q&A Discussion
10:30 - 10:45am BREAK
10:45am - 12:15pm S5. Session 5 - The Spectrum of Other Non-MS Inflammatory CNS Diseases
Chairs: Anastasia Zekeridou, Mayo Clinic
Dalia Rotstein, University of Toronto
Theme: This session will focus on non-MS CNS inflammatory and autoimmune disorders.
Learning Objectives: 1) To learn the latest regarding the pathophysiology underlying neuromyelitis optica and its treatment; 2) To learn about CNS inflammatory disorders due to checkpoint inhibitor therapy; 3) To be updated on the spectrum of autoimmune encephalitides
  10:45 - 10:50am Introduction
  10:50 - 11:05am S5.1 Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
Jeffrey Bennett, University of Colorado
  11:05 - 11:20am S5.2 NMO and Anti-MOG: Updates on Diagnosis and Treatment
Sean J. Pittock, Mayo Clinic
  11:20 - 11:35am S5.3 CNS Inflammatory Complications of Check-point Inhibitors
Matt Schindler, Penn Medicine
  11:35am - 11:50pm S5.4 Autoimmune Encephalitis
Divyanshu Dubey, MBBS Mayo
  11:50am - 12:15pm Q&A Discussion
12:15-12:30pm BREAK
12:30-1:00pm Brain Exchange Group Discussions: MS Care & Research in Women Across the Lifespan and MOG Antibody Disease
1:00 - 2:30pm S6. Session 6 - The Spectrum of Disease Severity: From Benign to Aggressive MS
Chairs: Fred Lublin, Mt. Sinai NYC
Erin Longbrake, Yale University
Theme: This session will focus on current understanding of MS subtypes of differing disease aggressiveness.
Learning Objectives: 1) To understand the differences between benign and aggressive MS clinically and based on imaging; 2) To examine the role of the innate immune system in progressive MS; 3) To learn about the subset of MS in which cognition is primarily affected
  1:00 - 1:05pm Introduction
  1:05 - 1:20pm S6.1 The Innate Immune System in Progressive MS
V. Wee Yong, University of Calgary
  1:20 - 1:35pm S6.2 Spectrum of Imaging Findings in Benign vs. Aggressive MS
Robert Naismith, Washington University at St. Louis
  1:35 - 1:50pm S6.3 Cerebral/Cognitive-Predominant MS
Claire Riley, Columbia University
  1:50 - 2:05pm S6.4 Benign MS and Aggressive MS – Nature or Nurture?
Mark Freedman, University of Ottawa
  2:05 - 2:30pm Q&A Discussion
2:30 - 2:45pm Closing Remarks
Jeffrey A. Cohen, Cleveland Clinic


On-Demand Symposia

On-Demand Symposia will be made available at 6:30 am CT on Thursday, February 25.

*Independent Industry Supported CME Satellite Symposia are not included in the ACTRIMS Forum 2021 accredited program.